Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 6/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | SPR | P35270 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11888928 | 0.84 | PKM (0.53) | CYP2D6KMT2ACYP2C9 | |
| SCHEMBL11888859 | 0.81 | KMT2A (0.65) | CYP2D6KMT2AMEN1 | |
| SCHEMBL1147128 | 0.80 | MAPT (0.44) | LIPECHRM1KDM2BRORC | |
| SCHEMBL11888832 | 0.80 | PKM (0.51) | CYP2D6KMT2AMEN1 | |
| SCHEMBL11889050 | 0.78 | FAAH (0.52) | CYP2D6KMT2ACCR1 | |
| SCHEMBL24754403 | 0.78 | CHRM1 (0.53) | LIPECHRM1KMT2AAKR1C3MMP2 | |
| SCHEMBL29784737 | 0.78 | CHRM1 (0.53) | LIPECHRM1KMT2AAKR1C3MMP2 | |
| SCHEMBL11888860 | 0.78 | KMT2A (0.58) | LIPECYP2D6KMT2AMEN1MMP13 | |
| SCHEMBL28663136 | 0.78 | TSHR (0.62) | LIPECHRM1KDM2BKMT2AMEN1 | |
| SCHEMBL31684033 | 0.78 | TSHR (0.62) | LIPECHRM1KDM2BKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102471265-B | Piperidine derivatives and their use for the treatment of obesity, diabetes, dyslipidemia and atherosclerosis | HOFFMANN LA ROCHE | 2014-09-03 | — | — | CN | claimed |
| EP-2480532-B1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | claimed |
| US-8399676-B2 | Piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | claimed |
| EP-2480532-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | claimed |
| CN-102471265-A | Piperidine derivatives and their use for the treatment of obesity, diabetes, dyslipidemia and atherosclerosis | HOFFMANN LA ROCHE | 2012-05-23 | — | — | CN | claimed |
| CN-102471265-B | Piperidine derivatives and their use for the treatment of obesity, diabetes, dyslipidemia and atherosclerosis | HOFFMANN LA ROCHE | 2014-09-03 | — | — | CN | disclosed |
| EP-2480532-B1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8399676-B2 | Piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2480532-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| CN-102471265-A | Piperidine derivatives and their use for the treatment of obesity, diabetes, dyslipidemia and atherosclerosis | HOFFMANN LA ROCHE | 2012-05-23 | — | — | CN | disclosed |